

8
DMJ
12/13/01



PATENT APPLICATION
ATTORNEY DOCKET 29715/33638A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ammons *et al.*

Serial No: 09/416,828

Filed: October 12, 1999

For: "Method of Treating Conditions
Associated with Intestinal
Ischemia/Reperfusion"

Group Art Unit: 1647

Examiner: D. Romeo

) I hereby certify that this paper is
being deposited with the United
States Postal Service as First
Class Mail, postage prepaid in
an envelope addressed to:
Commissioner for Patents,
Washington, D.C. 20231, on
this date:
)
November 30, 2001
)

Jeffrey S. Sharp
Registration No. 31,879

TERMINAL DISCLAIMER UNDER 37 C.F.R. §1.321(c)

Commissioner for Patents
Washington, D.C. 20231

Sir:

XOMA Technology Ltd. is the owner of the entire right, title, and interest in the above-identified patent application as shown by the assignment recorded on September 5, 1995 at Reel 7626, Frame 99 in grandparent application U.S. Serial No. 08/232,527 and is the assignee of United States Patent Nos. 5,578,568 and 6,017,881 by virtue of the same assignment. XOMA Technology Ltd. is a wholly-owned subsidiary of XOMA Ltd., 2910 Seventh Street, Berkeley, California 94710, both of which are limited liability companies of Bermuda (a dependent territory of the United Kingdom) and wherein XOMA Ltd. has resulted from merger and change of domicile of XOMA Corporation. XOMA Technology Ltd. is the owner of the entire right, title, and interest in the above-identified patent application as a consequence of a letter agreement executed by the inventor on July 15, 1998 and is also the owner of the entire right, title and interest

12/13/2001 GTRAMMEL in United States Patent Nos. 5,578,568 and 6,017,881.

01 FC:148

110.00 CH


Owner hereby disclaims the terminal portion of the term of any patent granted on the above-identified application extending beyond the expiration dates of United States Patent Nos. 5,578,568 and 6,017,881, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent and the legal title to United States Patent Nos. 5,578,568 and 6,017,881 are commonly owned, this agreement to run with any patent granted on the above-entitled application and to be binding upon owner and its successors or assigns.

Owner does not disclaim any terminal portion of the term of any patent granted on the above-identified application prior to the expiration date of the full statutory term of United States Patent Nos. 5,578,568 or 6,017,881, in the event that said United States Patent Nos. 5,578,568 or 6,017,881 later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or in part or are terminally disclaimed under 37 CFR 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to expiration of its statutory term, except for the separation of legal title stated above.

The documents establishing the owner's chain of title have been reviewed by the undersigned and the undersigned certifies that to the best of his/her knowledge and belief, title is in the owner.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

XOMA Technology Ltd.


By: Jeffrey S. Sharp
Attorney for XOMA Technology Ltd.

Date: November 30, 2001